We are pleased to present new preclinical data on our novel IP-receptor agonist, CS585. Through prolonged anti-thrombotic efficacy and high selectivity for the IP receptor, CS585 offers a promising new approach to anti-platelet therapy for thrombotic diseases, said Sten. R Sörensen, CEO Cereno Scientific.

The abstract titled "Selectivity and Long Action of In Vivo Efficacy of CS585, a Novel Prostacyclin Receptor Agonist, Compared to FDA-Approved Prostacyclin Agonists Iloprost and Selexipag in the Prevention of Thrombosis", was authored by L. Stanger, M Flores, K Goerger och M. Holinstat, vid University of Michigan, Ann Arbor, USA; and B. Dahlöf, Cereno Scientific.

The poster was presented by Livia Stanger, Graduate student at the Holinstat Lab at University of Michigan, led by Prof. Michael Holinstat, Professor in the Department of Pharmacology, the Department of Internal Medicine (Division of Cardiovascular Medicine), and the Department of Vascular Surgery at the University of Michigan. Prof. Holinstat leads Cereno's development programs at the University of Michigan and is Director of Translational Research at Cereno.

Read the full abstract here.

The abstract and poster present a comparison of the selectivity profiles of CS585, iloprost and selexipag in washed human platelets, human whole blood and mice lacking the IP receptor, and an evaluation of the duration of effects in vivo in wild-type (WT) mice for prevention of platelet activation and thrombosis.

The new data indicates that CS585 is highly selective for the IP receptor and does not affect clot lysis.  The study demonstrates that CS585 inhibits thrombus formation specifically via IP receptor agonism.  In both in vivo and ex vivo models, non-selective effects of iloprost and selexipag were observed, in addition to confirming the limitations of length of effect in the blood previously reported in the literature.  CS585 also provides prolonged inhibition of thrombus formation for at least 24 hours post-administration.

About ASH

The ASH (American Society of Hematology) Annual Meeting and Exposition is one of the world's largest conferences for professionals in hematology, including clinicians, scientists, and researchers. The conference features trends and discoveries in hematology followed by panel discussions and Q&As. This year's edition marks the 66th conference since its inception, and the conference is an important part of the development and growth in hematology.

About CS585

Drug candidate CS585 is an oral, highly potent, and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension.

A license agreement for drug candidate CS585 with the University of Michigan provides Cereno exclusive rights to further development and commercialization of CS585.

In early November 2023, CS585 was highlighted by top-tier medical journal Blood as a promising novel anti-thrombotic strategy without risk of bleeding.

Preclinical data for Cereno Scientific's novel IP Receptor Agonist CS585 was presented at ESC Congress 2024, indicating that CS585 inhibits platelet activation and clot formation up to 24 hours post-administration.

For further information, please contact:

Julia Fransson, Director Business Development

Email:  julia.fransson@cerenoscientific.com

Phone: +46 708-14 31 75

Sten R. Sörensen, CEO

Email: sten.sorensen@cerenoscientific.com

Phone: +46 73-374 03 74

About Cereno Scientific AB

Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full.

Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1's safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. HDACi CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 employs a multi-modal mechanism of action as an epigenetic modulator, targeting key unmet needs in patients with rare disease Idiopathic Pulmonary Fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension.

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information on www.cerenoscientific.com.